Assessment of the influence of expanded hemodialysis on the rate of removal of middle molecular weight uremic toxins

Q4 Medicine
M. Nenadović, A. Nikolic, M. Kostović, Branislava Drašković, M. Jovanovic, T. Nikolić, D. Petrovic
{"title":"Assessment of the influence of expanded hemodialysis on the rate of removal of middle molecular weight uremic toxins","authors":"M. Nenadović, A. Nikolic, M. Kostović, Branislava Drašković, M. Jovanovic, T. Nikolić, D. Petrovic","doi":"10.5937/MCKG54-30496","DOIUrl":null,"url":null,"abstract":"Objective. The aim of this study was to examine the effect of expanded hemodialysis on the degree of b2-microglobulin removal. Methods. Sixteen patients treated with extended MCO hemodialysis were examined. The main parameter for assessing the efficiency of removal of uremic toxins of middle molecular weight is the concentration of b2-microglobulin in the serum before and after a single session of extended MCO hemodialysis. The following were used for statistical analysis: Kolmogorov-Smirnov test, Student's T test for bound samples and Wilcoxon test. Results. Extended MCO hemodialysis effectively removes uremic toxins of middle molecular weight. The reduction index of b2-microglobulin during a single session of extended MCO hemodialysis is 70.60 ± 5.88%. The average loss of albumin during a single session of extended MCO hemodialysis is 1.88 ± 1.02 g/4h, and the index of albumin reduction is 4.94 ± 2.49%. Conclusion. Extended MCO hemodialysis effectively removes b2-microglobulin. The b2-microglobulin reduction index is ~ 71% and the albumin loss is less than 4.0 g/4h. This dialysis modality prevents the development of amyloidosis, atherosclerosis and atherosclerotic cardiovascular diseases in the population of patients treated with regular hemodialysis.","PeriodicalId":39117,"journal":{"name":"Medicinski Casopis","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinski Casopis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/MCKG54-30496","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Objective. The aim of this study was to examine the effect of expanded hemodialysis on the degree of b2-microglobulin removal. Methods. Sixteen patients treated with extended MCO hemodialysis were examined. The main parameter for assessing the efficiency of removal of uremic toxins of middle molecular weight is the concentration of b2-microglobulin in the serum before and after a single session of extended MCO hemodialysis. The following were used for statistical analysis: Kolmogorov-Smirnov test, Student's T test for bound samples and Wilcoxon test. Results. Extended MCO hemodialysis effectively removes uremic toxins of middle molecular weight. The reduction index of b2-microglobulin during a single session of extended MCO hemodialysis is 70.60 ± 5.88%. The average loss of albumin during a single session of extended MCO hemodialysis is 1.88 ± 1.02 g/4h, and the index of albumin reduction is 4.94 ± 2.49%. Conclusion. Extended MCO hemodialysis effectively removes b2-microglobulin. The b2-microglobulin reduction index is ~ 71% and the albumin loss is less than 4.0 g/4h. This dialysis modality prevents the development of amyloidosis, atherosclerosis and atherosclerotic cardiovascular diseases in the population of patients treated with regular hemodialysis.
扩大血液透析对中分子量尿毒症毒素脱除率影响的评价
目标。本研究的目的是检查扩大血液透析对b2微球蛋白去除程度的影响。方法。对16例延长MCO血液透析患者进行了检查。评估中等分子量尿毒症毒素清除效率的主要参数是在单次延长MCO血液透析前后血清中b2微球蛋白的浓度。采用Kolmogorov-Smirnov检验、Student’s T检验和Wilcoxon检验进行统计分析。结果。延长MCO血液透析可有效去除中等分子量的尿毒症毒素。延长MCO单次血液透析期间b2微球蛋白降低指数为70.60±5.88%。延长MCO血液透析单次平均白蛋白损失为1.88±1.02 g/4h,白蛋白降低指数为4.94±2.49%。结论。延长MCO血液透析有效去除b2微球蛋白。b2-微球蛋白减少指数为~ 71%,白蛋白损失小于4.0 g/4h。这种透析方式可以防止淀粉样变性、动脉粥样硬化和动脉粥样硬化性心血管疾病在接受常规血液透析治疗的人群中的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicinski Casopis
Medicinski Casopis Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信